89bio Yönetim

Yönetim kriter kontrolleri 2/4

89bio's CEO is Rohan Palekar, appointed in Jul 2018, has a tenure of 6.33 years. total yearly compensation is $5.59M, comprised of 10.9% salary and 89.1% bonuses, including company stock and options. directly owns 0.27% of the company’s shares, worth $2.60M. The average tenure of the management team and the board of directors is 3.3 years and 4.3 years respectively.

Anahtar bilgiler

Rohan Palekar

İcra Kurulu Başkanı

US$5.6m

Toplam tazminat

CEO maaş yüzdesi10.9%
CEO görev süresi6.3yrs
CEO sahipliği0.3%
Yönetim ortalama görev süresi3.3yrs
Yönetim Kurulu ortalama görev süresi4.3yrs

Son yönetim güncellemeleri

Recent updates

89bio: Surviving A Competitive Space - For Now

Oct 29

Health Check: How Prudently Does 89bio (NASDAQ:ETNB) Use Debt?

Sep 26
Health Check: How Prudently Does 89bio (NASDAQ:ETNB) Use Debt?

89bio: Bullish In Light Of Further MOA Being Established By Peer

Aug 07

89bio: Pegozafermin Could Be A Game-Changer For Liver Disease - Strong Buy

May 23

89bio Still Has A Chance As NASH Race Heats Up

Oct 06

89bio completes enrollment in phase 2 trial for NASH treatment

Aug 18

89Bio rallies on Deep Track Capital disclosing 10% stake

Jul 07

89bio: Undervalued Contender In Race For First NASH Drug Approval

Jul 20

We're Hopeful That 89bio (NASDAQ:ETNB) Will Use Its Cash Wisely

May 07
We're Hopeful That 89bio (NASDAQ:ETNB) Will Use Its Cash Wisely

89bio: NASH Drug Developer With Differentiated Profile

Jan 29

We're Hopeful That 89bio (NASDAQ:ETNB) Will Use Its Cash Wisely

Jan 22
We're Hopeful That 89bio (NASDAQ:ETNB) Will Use Its Cash Wisely

89bio expects to initiate Phase 2b NASH trial in 1H21

Jan 05

CEO Tazminat Analizi

Rohan Palekar'un ücretlendirmesi 89bio'un kazancına kıyasla nasıl değişti?
TarihToplam TazminatMaaşŞirket Kazançları
Jun 30 2024n/an/a

-US$175m

Mar 31 2024n/an/a

-US$165m

Dec 31 2023US$6mUS$611k

-US$142m

Sep 30 2023n/an/a

-US$127m

Jun 30 2023n/an/a

-US$119m

Mar 31 2023n/an/a

-US$105m

Dec 31 2022US$3mUS$588k

-US$102m

Sep 30 2022n/an/a

-US$104m

Jun 30 2022n/an/a

-US$105m

Mar 31 2022n/an/a

-US$101m

Dec 31 2021US$5mUS$565k

-US$90m

Sep 30 2021n/an/a

-US$76m

Jun 30 2021n/an/a

-US$63m

Mar 31 2021n/an/a

-US$54m

Dec 31 2020US$5mUS$530k

-US$49m

Sep 30 2020n/an/a

-US$56m

Jun 30 2020n/an/a

-US$60m

Mar 31 2020n/an/a

-US$64m

Dec 31 2019US$1mUS$431k

-US$57m

Sep 30 2019n/an/a

-US$44m

Jun 30 2019n/an/a

-US$30m

Dec 31 2018US$708kUS$195k

-US$18m

Tazminat ve Piyasa: Rohan's total compensation ($USD5.59M) is above average for companies of similar size in the US market ($USD3.24M).

Tazminat ve Kazançlar: Rohan's compensation has increased whilst the company is unprofitable.


CEO

Rohan Palekar (58 yo)

6.3yrs

Görev süresi

US$5,587,661

Tazminat

Mr. Rohan Palekar serves as the Chief Executive Officer and Director at 89bio, Inc. since July 16, 2018. He is an Independent Director at Neoleukin Therapeutics, Inc since March 02, 2022 and Neurogene Inc....


Liderlik Ekibi

İsimPozisyonGörev süresiTazminatSahiplik
Rohan Palekar
CEO & Director6.3yrsUS$5.59m0.27%
$ 2.6m
Quoc Le-Nguyen
Chief Technical Officer5.7yrsUS$2.51m0.15%
$ 1.4m
Harry Mansbach
Chief Medical Officer5.9yrsUS$2.54m0.088%
$ 854.6k
Ryan Martins
Chief Financial Officer5.3yrsVeri yok0.042%
$ 409.8k
Francis Sarena
Chief Operating Officerless than a yearVeri yokVeri yok
Shiva Natarajan
Senior Vice President of Finance & Principal Accounting Officerno dataVeri yokVeri yok
Annie Chang
VP of Investor Relations & Corporate Communicationsless than a yearVeri yokVeri yok
Amanda Kurihara
Vice President of People & Culture3.8yrsVeri yokVeri yok
Melissa Abel
Senior Vice President of Commercial Strategyno dataVeri yokVeri yok
Paul Shin
Senior Vice President of R&D Operations2.8yrsVeri yokVeri yok
Michael Baldwin
Senior VP & Head of Quality1.8yrsVeri yokVeri yok
Teresa Perney
Chief Regulatory & Quality Officerless than a yearVeri yokVeri yok

3.3yrs

Ortalama Görev Süresi

57yo

Ortalama Yaş

Deneyimli Yönetim: ETNB's management team is considered experienced (3.3 years average tenure).


Yönetim Kurulu Üyeleri

İsimPozisyonGörev süresiTazminatSahiplik
Rohan Palekar
CEO & Director6.3yrsUS$5.59m0.27%
$ 2.6m
Kathleen LaPorte
Independent Director3yrsUS$360.17k0%
$ 0
Lota Zoth
Independent Director4.3yrsUS$363.33k0%
$ 0
Michael Hayden
Independent Director6.6yrsUS$358.33k0.23%
$ 2.3m
Martin Babler
Independent Directorless than a yearVeri yokVeri yok
Steven Altschuler Buser
Independent Chairman of the Board4.7yrsUS$385.83k0%
$ 0
Charles McWherter
Directorless than a yearVeri yokVeri yok
Edward Atkinson
Independent Director2.8yrsUS$354.60k0%
$ 0
Derek DiRocco
Independent Director6.6yrsUS$352.33k0%
$ 0

4.3yrs

Ortalama Görev Süresi

62yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: ETNB's board of directors are considered experienced (4.3 years average tenure).